1,904.50p
+0.77%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GSK plc
Its shares trade on LSE under the ticker GSK.L. It has been listed since 22 May 1972. It is a member of the FTSE 100. In the fiscal year to 31 December 2025, it reported revenue of £32.67bn and net income of £5.72bn. At that date it held total assets of £61.12bn and shareholders' equity of £16.38bn.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex. The firm operates through two segments: Pharmaceuticals and Vaccines. The firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The firm makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The company has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 May 1972
- Employees
- 94,066
- Website
- gsk.com ↗
Leadership
Pay as last reported
- Sir Jonathan SymondsIndependent Non-Executive Chairman of the Board£781,000
- Dame Emma WalmsleyChief Executive Officer, Executive Director, since 2011£10.6m
- Mr. David RedfernPresident - Corporate Development
- Mr. Regis SimardPresident - Global Supply Chain
- Mr. Phil ThomsonPresident - Global Affairs
- Ms. Deborah WaterhouseChief Executive Officer, ViiV Healthcare and President - GSK Global Health
- Ms. Diana ConradChief People Officer
- Mr. James FordSenior Vice President, Group General Counsel, Legal and Compliance
- Ms. Sally JacksonSenior Vice President - Global Communications and CEO Office
- Ms. Shobie RamakrishnanChief Digital and Technology Officer
- Dr. Tony WoodChief Scientific Officer
- Mr. Luke MielsChief Commercial Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 83
- Social
- 96
- Governance
- 85
- Direct emissions (scope 1)
- 521,000 t
- Energy emissions (scope 2)
- 234,000 t
- Value chain emissions (scope 3)
- 4,640,000 t
- Women in the workforce
- 48%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GSK operates in the health care sector with a focus on pharmaceuticals.
- The company employs 94,066 full-time staff members globally.
- Its research covers respiratory diseases, HIV, and vaccines.
Weaknesses
- The source description is explicitly treated as untrusted facts.
- Specific financial metrics and revenue figures are not provided.
- Competitive positioning details are absent from the input data.
Opportunities
- The firm focuses on research in oncology and rare diseases.
- Its vaccines business serves people of all ages including travelers.
- The company develops medicines for acute and chronic conditions.
Threats
- Regulatory changes in the pharmaceutical industry pose risks.
- Competitors in the health care sector may innovate faster.
- Market fluctuations could impact the value of its portfolio.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.